Related Experiment Video
Updated: Aug 9, 2026
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Applications of new laboratory marker assays in neurological diagnoses - a pilot study
David Stejskal1, Jitka Vavrousková, Jan Mares
1Department of Laboratory Medicine, Sternberk Hospital, Czech Republic. david.stejskal@quick.cz
Abstract:
225 consecutive patients with different neurological diseases and 101 individuals as the control were examined between 2002-2004. Cystatin C, arginase-I, tau-protein and beta-amyloid were measured. Individuals with CNS inflammation had significantly lower Cystatin-C index (CSF/serum) values. There was no diagnostic significance of the Arginase-I assay in CSF was verified. The CSF tau-protein/beta-amyloid index was shown to be a sufficient efficacy for neurodegenerative disease diagnosis.
More Related Videos
10:08Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid for the Detection of Central Nervous System Pathogens
Published on: April 17, 2026
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020